

TREK DIAGNOSTIC SYSTEMS

TREK

Times

INSIDE THIS ISSUE:

TREK Honors Thoroughly Outstanding Professionals in Microbiology	2
Willis-Knighton Health System Incorporated ARIS® 2X to Expand AST Offerings	3
TREK Introduces New VersaTREK Customer: Campbell County Memorial Hospital	4
TREK Welcomes Dr. Hiroshi Uchida: New President and CEO of Magellan Biosciences	5
Are you CLSI ready? Sensititre® CLSI-Ready Gram Negative MIC Plate is the Answer	6
Rapid Recovery of <i>Campylobacter</i> sp. in our VersaTREK® System	7
New VersaTREK Windows Software Features Numerous Enhancements	8
Updated Xtra Results for Gram Negative Organisms: How are you testing Colistin and Polymyxin B?	9
TREK Honors Three Distinguished VersaTREK Sites	10
TREK at ASM and Workshops	10

Correction: In the 2009 Fall TREK Clinical Times, we ran a case study of *Gardenerella vaginalis* sepsis. The accompanying photo in the article was not of *G. vaginalis* with "clue cells". We regret the error.

NEWS AND INSIGHT FOR THE CLINICAL MICROBIOLOGY LABORATORY

NewProduct•Announcement

NEW-- Sensititre® MTB MIC Plate*:

The first dry MIC plate for *M. tuberculosis* susceptibility testing


By Jenny Lorbach, Director of Marketing for Sensititre, TREK Diagnostic Systems

TREK announces the availability of an MIC plate (Part No. MYCOTB* in US, MYCOTBI* outside of US) for *M. tuberculosis* isolates. The MIC plate contains 12 first and second line antimicrobics on a single MIC platform.

Laboratories that implement this new MIC plate will benefit in the following ways:

- Faster time to results- only 10-21 days incubation; resistant isolate results available after 7-10 days incubation
- Obtain results for first and second line antimicrobics at the same time, improving turnaround time
- Inclusive positive control wells provide a reference for reading
- Permanent seal on each MIC plate ensures safety
- Easy set-up and incubation requirements
- Individual packaging for each MIC plate
- Manual or Vizion® Digital MIC Viewing System read options

Setting up the MIC plates is simple and requires the use of Saline Tween with Glass



The new *Mycobacterium tuberculosis* MIC plate contains 12 first and second line antimicrobics on a single MIC platform, improving turnaround time and reducing the cost per test.

Beads (5ml; Part No. T3490* in US) or T3491* (outside the US) and 7H9 Broth with OADC (11ml; Part No. T3440* in US) or T3441* (outside the US). It is recommended that laboratories utilize Sensititre Saline Tween with Glass Beads and Sensititre 7H9 OADC broth because all products undergo rigorous testing to ensure quality results. TREK also recommends using *M. tuberculosis* ATCC 27294 and ATCC 25177 strains to perform quality control procedures.

While reading the MTB plates, technologists can utilize a manual view box (Part No. V4007) and record results manually or read with the Vizion Digital MIC Viewing System. The Vizion System (Part No. V2020-SYS) allows technologists to immediately view the MTB isolate on a computer monitor.

(continued on p. 2)

*For research use only. Not for use in diagnostic procedures.

NewProduct•Announcement

MTB Plate* (continued from p. 1)

The SWIN software allows technologists to read the image and select the MIC well providing instant feedback regarding the susceptibility result. The image can be stored for later review, and used for teaching or training purposes.

These MIC plates have a 12-month shelf life at room temperature, and are individually sealed and packaged 10 per box to minimize waste. We anticipate international availability with CE mark for IVD use soon. Contact TREK Customer Service or your Area Account Manager at 800-871-8909, or internationally at +44 (0) 1342 318777 for more information on the new *Mycobacterium tuberculosis* MIC plate.

**For research use only. Not for use in diagnostic procedures.*



Technologists can manually read and record MIC results using the Vizion Digital MIC Plate Viewer, which provides instant feedback regarding susceptibility results.

Antimicrobics and Dilution Ranges for the *M. tuberculosis* Plate (Part No. MYCOTB*, MYCOTBI*)

Antimicrobic	Dilution (µg/ml)
Amikacin	0.12-16
Cycloserine	2-256
Ethambutol	0.5-32
Isoniazid	0.03-4
Kanamycin	0.6-40
Moxifloxacin	0.06-8
Ofloxacin	0.25-32
Para-amino-salicylic acid	0.5-64
Rifabutin	0.12-16
Rifampin	0.12-16
Streptomycin	0.25-32

TREK•News

TREK Honors Thoroughly Outstanding Professionals in Microbiology

By DeAna Paustian, Senior Marketing Specialist, TREK Diagnostic Systems

As a dedicated microbiology company, TREK Diagnostic Systems values the outstanding partnerships we have formed throughout the years in the microbiology community.

We understand how important our customers are to the success of our organization, and future growth. In fact, the cornerstone of our quality policy is dedicated to promoting customer satisfaction, consistent quality and continuous improvement in our products.

To demonstrate our appreciation and recognize our loyal VersaTREK customers, we are pleased to announce the VersaTREK TOP Customer Award Program. Sites are nominated for the award either by their Area Account Manager, or the VersaTREK Marketing

Team for their exemplary dedication to the VersaTREK product line.

Examples of this dedication include; hosting site visits for potential customers, speaking to potential customers about their VersaTREK experiences and providing testimonials for sales and marketing promotions and literature.

We are very fortunate to have so many customers speak on our behalf regarding their positive experiences. Now, it is our time to give a little something back to our TOP customers.

TREK Diagnostic Systems is pleased to announce **Affiliated Laboratory, Inc.** (Bangor, ME), **Alexian Brothers Medical Center** (Elk Grove Village, IL)

and **The Medical Center** (Columbus, GA) as the first recipients of the VersaTREK TOP customer award!

The individuals at this site are Thoroughly Outstanding Professionals and TREK has had the distinct pleasure of partnering with them. To read more about these sites please turn to page 10 or visit our website at www.trekds.com.

Watch for the TREK Clinical Times Fall 2010 edition for details on our upcoming Sensititre TOP Customer Award Program!

Customer Profile

Willis-Knighton Health System Incorporates ARIS® 2X to Expand AST Offerings

By Regina Galloway, B.S., MT and Heather Piwonka, M.S., SM,
Assistant Microbiology Supervisors, Willis-Knighton Health System

Willis-Knighton Health System is an 800-bed, four-hospital community health system located in metropolitan Shreveport, Louisiana. Our central Microbiology Laboratory serves a four-hospital system, as well as a Cancer Center and a large outpatient population in North Louisiana, Southern Arkansas and East Texas. We generate approximately 150,000 billable tests annually, with 80,000 of those tests being bacteriology, mycology and mycobacteriology cultures.

Our laboratory is one of the largest and busiest in Louisiana. Due to our large workload, we have made innovative changes to make our department more efficient and improve our turnaround times. One of the more practical applications we have brought in is the use of Sensititre® MIC plates to provide our physicians with a wider range of antimicrobial treatment options for their patients.

We validated Sensititre plates to test many of the more fastidious organisms. In addition, we provide a susceptibility plate for significant strictly anaerobic isolates using the Sensititre anaerobic MIC plate (Part No. ANO2B*). We routinely set up *Streptococcus pneumoniae*, beta-hemolytic streptococci, viridians streptococci, and *Haemophilus influenzae/parainfluenzae* using Sensititre Streptococcus plate (Part No. STP6F) and *Haemophilus* plate (Part No. HPB).

In 2008, we truly revolutionized the processing of Sensititre plates by adding the ARIS 2X, the AutoInoculator and the Vizion® instruments. By adding these components, we reduced our set-up time, decreased time spent reading plates manually, and advanced manual plate



Willis-Knighton Health System uses Sensititre MIC plates to provide their physicians with, "a wider range of antimicrobial options for their patients."

reading with the touch screen applications of the Vizion System. The time savings these provided gave us more time for other value-added tasks.

Currently, we use the ARIS 2X System to test staphylococcal isolates. Our hospital information system (HIS) is interfaced with the SWIN software, which allows our technologists to review sensitivities at their computers before reporting results to the physicians.

The driving force to move all staphylococcus isolates to the Sensititre System was the Gram positive susceptibility plate (Part No. GPALL1F). This plate includes a cefoxitin screen, D-test and daptomycin— a dream come true for our infectious disease doctors! In addition to the benefits already mentioned, moving staphylococcal susceptibility testing to the ARIS 2X System decreased the demand on our primary, rapid instrument, which was consistently filled to capacity.

Implementing automated testing required a lot of teamwork and

flexibility. Staphylococcal MIC testing on our rapid instrument took only about 8-12 hours to complete, but the new Gram positive plate required 24-hour incubation. We did not want this increase in turnaround time to negatively affect our patients, so our department felt it was important to try to get *Staphylococcus* isolates to the ARIS as quickly as possible.

The Microbiology staff deserves credit for re-evaluating workflow and finding ways to improve it. Now, when reading new cultures, we set up *Staphylococcus aureus* MIC panels immediately using the AutoInoculator to speed the process. As they are reading cultures, technologists prepare Sensititre demineralized water suspensions at the bench, and pass those suspensions to the technologist who is inoculating Sensititre plates for the entire lab. On busy days, we can easily inoculate over 30 GPALL1F panels.

Most recently, we have shifted *Pseudomonas aeruginosa* susceptibility testing to the ARIS 2X System. Over time, Sensititre has come to play an increasing role in our day-to-day operations. Our technologists feel very comfortable with the instrumentation, and like the fact that it is so simple. We believe that TREK Sensititre plays a significant role in making our laboratory a recognized leader in providing accurate and timely microbiology services.

**For research use only. Not for use in diagnostic procedures.*

“ Sensititre plays a significant role in making our laboratory a recognized leader in providing accurate and timely microbiology services. ”

Customer Profile

TREK Introduces New VersaTREK® User: Campbell County Memorial Hospital!

By Lynn Todd, Laboratory Manager, Campbell County Memorial Hospital and DeAna Paustian, Senior Marketing Specialist, TREK Diagnostic Systems

In 1953, the medical needs in the community of Gillette, Wyoming were served by only four physicians and one visiting surgeon in a small 31-bed red brick hospital. As the community grew, so did the healthcare system. In 1981, Campbell Community Hospital opened. This 90-bed hospital system has continued to expand, with a new parking structure being erected, as well as new patient floors.

According to the Campbell County Community Hospital website, "As the community grows and changes, Campbell County Memorial Hospital will continue to develop programs and services to meet the healthcare needs of our citizens."

The lab at Campbell County employs 26 staff members with 5 specifically trained in microbiology. The lab performs 780,000 chemistry tests and approximately 2,500 blood culture sets annually. Prior to the installation of the VersaTREK, the site had two BACTEC™ 9050s.

T: What made you decide to choose VersaTREK for your blood culture and mycobacteria needs?

CCMH: We feel VersaTREK is better at recovering organisms and recovers more organisms because of the instrument's detection technology. It is not limited to CO₂ production, like its competitors. For our laboratory, the VersaTREK is less expensive and we can expand our testing with the existing footprint, which is a desirable feature.

T: What was your impression of the conversion process from your previous system to VersaTREK?

CCMH: It had been a while since we performed validation studies, so that took some time to get used to. How-



According to Lynn Todd, "We feel VersaTREK is better at recovering organisms and recovers more organisms because of the instrument's detection technology."

ever, the conversion process itself was good.

T: What were your impressions of the on-site training?

CCMH: The on-site training was very good. The trainers were knowledgeable and responsive to questions, making time to train many staff on a one-to-one basis to fit in with our schedule.

T: What are your impressions of TREK's customer service?

CCMH: Customer service is very good. The whole TREK team, including sales, has been a pleasure to work with.

T: What do you and your lab like about the system?

CCMH: We like the fact that VersaTREK is expandable and that we can use the system for sterile body fluids, as the

VersaTREK is FDA-cleared for this application. We are not currently interfaced, but we are looking forward to all the reports once we interface VersaTREK with MediTech.

T: Have you recovered any unusual organisms since using VersaTREK?

CCMH: Yes, we have recovered *Salmonella* sp. and *Campylobacter* sp. which we had not recovered in the past.

T: Have you noticed any increase in recovery of certain organisms since the VersaTREK was brought into your lab?

CCMH: Absolutely. Compared to our previous system, VersaTREK has a faster time-to-detection, has been better at recovery and is easier to use.

Congratulations to Campbell County on their new VersaTREK instrument! We look forward to a long partnership and instrument expansion as they continue to grow and develop with the community.

“ VersaTREK has a faster time-to-detection, has been better at recovery and is easier to use. ”

TREK•News

TREK Welcomes Dr. Hiroshi Uchida: New President and CEO of Magellan Biosciences


Magellan Biosciences, Inc., the parent company of TREK Diagnostic Systems, recently introduced its new president and chief executive officer, Hiroshi Uchida, Ph.D. He will also serve as a company director. Dr. Uchida has more than 20 years of leadership experience in the global medical technology and management consulting industries.

He comes to Magellan from Fenwal, Inc., a leading supplier of advanced blood technologies, where he served most recently as executive vice president and chief technology officer, and then as a member of Fenwal's board of directors.

"Hiroshi brings to Magellan strategic insight, consummate skill in organizational development and a track record of success in building strong companies," said Herbert H. Hooper, chairman of Magellan's board of directors.

When Dr. Uchida joined Fenwal in 2006, he was charged with carving out the company from Baxter International and turning around company performance. Fenwal became an independent corporation in 2007. Dr. Uchida held numerous positions in sales, marketing, supply chain and R&D. He established the company's strategic direction and developed key processes to increase organizational effectiveness and efficiency. Under Dr. Uchida's leadership, product innovation and quality grew and the number of new product launches increased significantly.

Prior to Fenwal, Dr. Uchida held executive positions at Dade Behring, Inc., a leading manufacturer and distributor of in-vitro diagnostics (IVD) products and services to clinical laboratories. Previously, he was a global management consultant for Arthur D. Little, serving as director, Asia Pacific. He started his career at Bain and Company, where he



Hiroshi Uchida, Ph.D., President and Chief Executive Officer, Magellan Biosciences, Inc.

was vice president of the Tokyo office. Dr. Uchida holds both a Ph.D. in business studies and sociology, and a master's degree in sociology from Harvard University.

"There are many factors increasing the demand and importance of diagnostic testing – from demographics and an acute shortage of qualified lab personnel, to advances in both biomedical research and testing technology – and Magellan is well-positioned with automated and point-of-care platforms to take advantage of growth opportunities," said Dr. Uchida. "I'm honored to join Magellan and its team of dedicated and talented employees. Our three-pillar value-creation strategy to grow the company and serve customers even better includes:

- Improving productivity by sharing best practices and expertise across the company and through a lean, efficient operations platform;

- Driving organic growth by accelerating investments in breakthrough development projects that build on Magellan's track record of innovation and success in bringing products to market that make diagnostic testing easier, more cost-effective, and less labor-intensive;
- Partnering with synergistic companies that share Magellan's commitment to improving testing workflow."

New Product • Announcement

Are you CLSI 2010 ready?

Sensititre CLSI-Ready Gram Negative MIC Plate is the Answer

By Joan Lamprecht, Associate Product Manager, TREK Diagnostic Systems

This year, CLSI made major changes to its Enterobacteriaceae interpretive guidelines for cephalosporins and carbapenems. These changes (see tables, right) reflect what is known about today's isolates and their clinical response to agents using currently recommended dosage regimes.

Laboratories will be working to educate their infectious disease physicians, clinicians, pharmacy, infection control practitioners and P&T committees. During that time, many will be gathering information on the percentage of isolates whose categorical results will change with the new breakpoints.

Sensititre has a new IVD-labeled MIC plate to meet your laboratory needs today, during the transition and after adoption of the new guidelines. The 2010 CLSI-ready Gram negative MIC plate (*Part No. GN4F*) covers FDA and CLSI breakpoints (note: requires in-house validation per CLSI M100 S-20 guidelines). Additionally, the GN4F format contains minocycline and doripenem as the latest FDA-cleared antimicrobial additions.

Part No. GN4F

<u>Antimicrobial</u>	<u>Dilution(µg/ml)</u>
Amikacin	8-32
Ampicillin	8-16
Ampicillin/sulbactam	4/2-16/8
Aztreonam	1-16
Cefazolin	0.5-16
Cefepime	4-32
Ceftazidime	1-16
Ceftriaxone	0.5-32
Ciprofloxacin	0.5-2
Doripenem	0.5-4
Ertapenem	0.25-8
Gentamicin	2-8
Imipenem	0.5-8
Levofloxacin	1-8
Meropenem	0.5-8
Minocycline	1-8

Enterobacteriaceae Cephalosporin and Aztreonam MIC breakpoints* (µg/ml):

Agent	2009 (M100-S19)			Revised (M100-S20)		
	Susc	Int	Res	Susc	Int	Res
Cefazolin	≤8	16	≥32	≤1	2	≥4
Cefotaxime	≤8	16-32	≥64	≤1	2	≥4
Ceftizoxime	≤8	16-32	≥64	≤1	2	≥4
Ceftriaxone	≤8	16-32	≥64	≤1	2	≥4
Ceftazidime	≤8	16-32	≥32	≤4	8	≥16
Aztreonam	≤8	16-32	≥32	≤4	8	≥16

*CLSI M100-20

Enterobacteriaceae Carbapenem MIC breakpoints* (µg/ml):

Agent	2009 (M100-S19)			Revised (M100-S20)		
	Susc	Int	Res	Susc	Int	Res
Ertapenem	≤2	4	≥8	≤0.25	0.5	≥1
Imipenem	≤4	8	≥16	≤1	2	≥4
Meropenem	≤4	8	≥16	≤1	2	≥4
Doripenem	≤0.5			≤1	2	≥4

*CLSI M100-20 Spring Supplement

<u>Antimicrobial</u>	<u>Dilution(µg/ml)</u>
Nitrofurantoin	32-64
Piperacillin	16-64
Piperacillin/tazobactam	8/4-128/4
Ticarcillin/clavulanic acid	8/2-64/2
Tetracycline	4-8
Tigecycline	1-8
Tobramycin	2-8
Trimethoprim/sulfamethoxazole	2/38-4/76

This new standard format (*Part No. GN4F*) can be utilized manually, with the Vizion® Digital MIC Viewing System, or with the fully automated ARIS® 2X System. Sensititre's SWIN® software is fully capable of utilizing the FDA and new CLSI-recommended breakpoints.

Count on Sensititre to be the first to offer the latest antimicrobials and the most up-to-date formulary selections. Contact TREK Customer Service or your Area Account Manager at 800-871-8909, or internationally at +44 (0) 1342 318777 for more information on our latest Sensititre solution.

Case Study

Rapid Recovery of *Campylobacter* sp. on VersaTREK System

By Kimberly Ilg, Microbiology Supervisor, MT (ASCP) SM, Alexian Brothers Medical Center, Elk Grove Village, Illinois

Alexian Brothers Medical Center has used the TREK blood culture system since 1993. In fact, we were the first site to upgrade our ESP® to the VersaTREK System in 2003. We stayed with the system for numerous reasons, including the lack of SPS¹ in the aerobic bottles, and the ability to detect organisms that consume either before they produce CO₂, or for those that never really do produce CO₂.

Our laboratory has recovered numerous fastidious organisms over the years with the ESP and VersaTREK systems, including the one reported in this article.

A 20-year-old male patient presented to our ER with abdominal pain at RLQ and periumbilical area. His pain was constant, sharp and colicky and was associated with vomiting and diarrhea. Temperature was 99.5°F. He had no history of adhesions, alcohol abuse, bowel obstruction, cardiac disease, chronic abdominal pain, constipation, Crohn's disease, gallstones, gastritis or hernia.

The following laboratory results were obtained:

CBC: WBC - 11.2 with 77% segs, 5% bands, 9% lymphs and 9% monos

HGB = 14.6 g/dL

HCT = 41.2%

Electrolytes— within normal limits with the exception of potassium at 3.3 mEq/L (low)


AST and BILIRUBIN – elevated

LIPASE— within normal limits

A CAT scan of the abdomen showed the appendix in the upper limits of normal and was removed laparoscopically. The appendix was found to be inflamed. Postoperatively the patient had a fever spike of 103°F. Intraoperative finding was consistent with a non-perforated acute appendicitis.



The VersaTREK detected *Campylobacter* sp. at Alexian Brothers Medical Center in Elk Grove Village, Illinois.



The VersaTREK graph showed consumption, followed by gas production, pictured in the graph, above.

The patient was discharged after evaluation by an infectious disease physician, and was started on Cefepime and Metronidazole. Blood cultures were negative at time of discharge.

At 35 hours, both the aerobic and anaerobic blood cultures signaled positive on the VersaTREK system. The graph showed consumption, followed by gas production (see graph, right). Initial Gram stain result was no organisms seen. However, with the positive VersaTREK graph, we knew there was some organism in the bottle. A second microscopic exam was performed with Wayson stain and revealed "seagull" shaped rods resembling *Campylobacter* sp. A blood agar plate was placed in a microaerophilic environment at 42°C. Confirmation of *Campylobacter* sp. was determined by the following:

- Growth at 42°C
- Gram stain morphology
- Oxidase (+)
- Catalase (+)
- Hippurate (+)

In conclusion, the graphs supplied by the VersaTREK instrument are very handy in assisting users as to what is happening within the bottle. As I mentioned, the initial Gram stain showed no organisms but because the graph was positive we knew some organism was in the bottle and continued our work-up.

If your laboratory has an interesting sepsis case that you would like to share with TREK, please contact DeAna Paustian at 800-871-8909, ext. 104 or email at dpaustian@trekds.com.

¹SPS is an anticoagulant used in some blood culture media that can be toxic to certain strains of *H. influenzae*, *N. meningitidis*, *N. gonorrhoeae*, *P. anaerobius* and *Gardnerella vaginalis*.

New Product • Announcement

New VersaTREK® Windows® Software Features Numerous Enhancements

By DeAna Paustian, Senior Marketing Specialist, TREK Diagnostic Systems

Customers often rave about VersaTREK Software and its easy-to-operate Windows-based system. However, we still continuously strive to improve our products, which is why the new VersaTREK Windows Software version 5.4.3.15 incorporates several new features. We have made new enhancements to the Main Menu Display and Results Comments Field. The following briefly describes these features:

Main Menu Display

Available Locations Icon – Now located on the bottom toolbar. ①

Reserved Locations Icon – Added as a means of identifying the number of reserved locations in the instrument. ②

Unused Accessions – Now included on the bottom toolbar. The unused accession numbers are received from your LIS or entered manually, and will remain in the Enter Specimen screen until the associated bottles are inserted. ③

Configuration Screen

Numbers have been added to the drawers on the screen for easier instrument navigation.

Results Comments Dictionary

- Results comments are now populated through data dictionaries with a drop down menu. This will allow standardized entries and reduce entry time and memory usage. A TREK Technical Support Specialist can assist you with building a customized menu.
- Results comments will now appear on the Test History Report. In addition, if a user changes a lab result on a bottle, the event is recorded on the Test History Report.
- Additional “free text” comments can be entered into the Notes field and will appear in Test History reports.

Patient Location and Source Dictionaries

- These items are now populated through easy-to-use data dictionaries with drop down menus.


Bottle Scanning and Accession Changes

- When a single bottle is scanned into VersaTREK the test type will default to unpaired. When the second bottle of a pair is scanned it will change to paired. If no second bottle is scanned, the test type will remain unpaired.
- When changing accessions on a bottle set in the Utilities Screen, the instrument will automatically change both the aerobic and anaerobic accession numbers.
- The number of records is displayed at the top of each screen in the header bar.

We have made many enhancements, many of which were identified and requested by our customers. To ensure you are operating on the most current software version, look at the main menu display on your VersaTREK software. The version you are running is indicated at the top of the software display.

If you have not done so, we encourage you to complete your upgrade as soon as possible. We want you to begin to enjoy the new enhancements! Contact TREK Technical Support at 1-800-642-7029 for more information.

VersaTREK Main Menu Display Enhancements



TREK•News

Updated Xtra Results for Gram Negative Organisms: How are you testing Colistin* and Polymyxin B*?

By Joan Lamprecht, Associate Product Manager, TREK Diagnostic Systems

In 2009, Sensititre added its Gram negative Extra MIC format (*Part No. GNXF**) to the already popular Non Fermenter MIC format (*Part No. NF*) as a solution for testing the most resistant Gram negative isolates. The GNXF* format allows testing of colistin, polymyxin B, doxycycline, minocycline as well as doripenem, ertapenem, imipenem and tigecycline.

TREK offers this Research Use Only product in response to requests for colistin and polymyxin B MIC testing. CLSI M100 does list interpretive MIC guidelines for *Pseudomonas aeruginosa*, *Acinetobacter* sp. and non-Enterobacteriaceae for these lipopeptides. Until breakpoints are approved by the FDA, all colistin and polymyxin B testing products must remain a Research Use Only Designation and labeled as not for use in diagnostic procedures.

This year, the GNXF* format will be replaced by the Updated Gram negative Extra MIC format (*Part No. GNX2F**) with adjusted ertapenem coverage (0.25-4 µg/ml) incorporating the 2010 CLSI M100-S20 breakpoints for Enterobacteriaceae.

The GNX2F* format will have an 18-month shelf life with room temperature storage and can be read manually, with the Vizion Digital MIC Viewing System or with the fully automated ARIS 2X system.

Contact your TREK area account manager or TREK customer service representative at 800-871-8909 in the U.S. or internationally at +44 1342 31877 to learn more about ordering this format for your laboratory.

**For Research Use Only. Not for use in diagnostic procedures.*



The updated Gram negative MIC plate features adjusted ertapenem coverage, incorporating the 2010 CLSI breakpoints for Enterobacteriaceae.

Part No.:	NF	GNX2F
Antimicrobial	µg/ml	µg/ml
Amikacin	4-32	4-32
Amp/Sul	2/1-16/8	
Aztreonam	2-16	2-16
Carbenicillin	32-256	
Cefepime	2-16	2-16
Cefoperazone	4-32	
Cefotaxime	4-32	1-32
Ceftazidime	1-16	1-16
Ceftriaxone	4-32	
Chloramphenicol	2-16	
Ciprofloxacin	0.25-2	0.25-2
Colistin		0.25-4
Doripenem		0.12-2
Doxycycline		2-16
Ertapenem		0.25-4
Gentamicin	1-8	1-8
Imipenem	1-8	1-8
Levofloxacin	0.5-4	1-8
Meropenem		1-8
Minocycline		2-16
Piperacillin/Tazobactam	8/4-64/4	8/4-64/4
Piperacillin	8-64	
Polymyxin B		0.25-4
Sulfisoxazole	256	
Tetracycline	1-8	
Ticarcillin/Clavulanic Acid	16/2-128/2	16/2-128/2
Ticarcillin	8-64	
Tigecycline		0.25-8
Tobramycin	1-8	1-8
Trimethoprim/Sulfamethoxazole	0.5/9.5-4/76	0.5/9.5-4/76

Meet the Expert



Nadine Sullivan, Ph.D.

Chief Science Officer and Vice President of New Business Development
TREK Diagnostic Systems

Q: What do you feel is your most significant contribution to TREK and/or TREK product lines?

Dr. Sullivan: I was the Project Leader for the ESP instrument, and had significant input into the development of the VersaTREK instrument and software. The REDOX 1 and 2 media formulations were initially developed by me at Difco, TREK's predecessor organization. I continue to have very strong influences in software improvements.

Q: What do you enjoy the most about your role at TREK?

Dr. Sullivan: My relationships with everyone I work with at TREK, especially our customers.

Q: What is the most satisfying part of working with customers?

Dr. Sullivan: I have been working with customers for about 25 years. I have developed some very close relationships with our customers and value their friendship and candor. The most satisfying thing for me is to see the looks on their faces when we bring a new product to market and it is what they asked for.

NewProduct•Announcement

TREK Honors Three Distinguished VersaTREK Sites

By DeAna Paustian, Senior Marketing Specialist, TREK Diagnostic Systems

TREK Diagnostic Systems is honored to announce **Affiliated Laboratory, Alexian Brothers Medical Center** and **The Medical Center** as the first recipients of the VersaTREK TOP customer award! The individuals at this site are Thoroughly Outstanding Professionals and TREK has had the distinct pleasure of partnering with them.

Affiliated Laboratory, Inc.

The Microbiology Department at Affiliated Laboratory, Inc. serves as a regional reference laboratory, teaching and research facility, providing comprehensive clinical microbiology services to hospitals, health centers, physician office practices and long-term care facilities throughout Maine. The Department is directed by Kirk Doing, PhD; with research interests in rapid viral diagnostics, molecular infectious disease testing and emerging antibiotic resistance. Affiliated's Bacteriology Team includes 16 technologists with over 300 years of clinical microbiology experience, providing unparalleled

support and expertise in the reference laboratory business. Affiliated has used the VersaTREK system since January of 2008 after converting from the BD BACTEC system.

Alexian Brothers Medical Center

Alexian Brothers Medical Center is a 387-bed acute care hospital in Elk Grove Village, Illinois, that has offered comprehensive quality healthcare to the northwest suburbs of Chicago for over 40 years. Alexian Brothers has 900 physicians representing more than 80 surgical and medical specialties treat more than 18,000 inpatients and perform thousands of inpatient and outpatient surgeries.

Alexian Brothers has a very long history with TREK Diagnostics dating back to 1993 when they used the ESP system. They were also our first VersaTREK installation!

The Medical Center

The Medical Center is part of Columbus

Regional Healthcare System in Columbus, Georgia. It is a 415-bed teaching facility and performs approximately 1.2 million laboratory tests per year. As the regional leader for healthcare in West Georgia, its mission is ensuring the highest level of care for patients. This site converted to VersaTREK in April 2004 from the bioMerieux BacT/ALERT system.

Daniel Cullison, Microbiology Supervisor stated, "The microbiology department at The Medical Center considers it a distinct honor to have been chosen to receive this award as one of 3 VersaTREK TOP Customers in the country. It is through TREK's commitment to providing innovative products and outstanding customer service that has allowed our facility to maintain the highest level of diagnostic testing services available. We have developed a strong partnership with our friends at TREK to achieve this common goal."

See the latest in Microbiology with TREK at ASM and Workshops

TREK will be showcasing its wide range of innovative products for the clinical microbiology laboratory, including the new *Mycobacterium tuberculosis* MIC plate*, at this year's 110th American Society for Microbiology General Meeting in San Diego, CA, May 24-26, 2010.

Visit TREK at **Booth #126** to learn more about the VersaTREK Automated Microbial Detection System and Sensititre® ARIS® 2X Automated AST/ID System, and see demonstrations of the Vizion Digital MIC Viewing System allows technologists to immediately view isolates on a computer monitor.

For more information on all TREK products, stop by **Booth #126**.



Not making the trip to San Diego this year? TREK may be coming to a city near you! TREK Discovery Workshops give microbiology professionals the chance to meet the experts, and learn the latest advances in microbiology while earning P.A.C.E.® credits! Discover the scientific principles behind

blood culture and susceptibility products from the experts, hear testimonials from actual users and participate in hands-on product demonstrations.

This year's schedule includes:

Atlanta, GA- June 24

Houston, TX- July

Portland, OR- September

Phoenix, AZ- October

Hartford, CT- November

Visit www.trekds.com/workshops for more information.


**For research use only. Not for use in diagnostic procedures.*

THE TOUGH BUGS CAN'T HIDE FROM TREK!

.....



**TREK Supports
National Medical
Laboratory
Professionals Week
April 18-24, 2010**



VersaTREK® and Sensititre®: A winning combination in the fight against tough bugs!

The VersaTREK Microbial Detection System offers a unique comprehensive detection system capable of detecting the toughest organisms. The Sensititre ID/AST system offers a fully customizable testing platform for even the most resistant or fastidious organisms. Sensititre offers complete ID/AST options, including manual and fully automated products with the greatest number of FDA-cleared antimicrobials, including Minocycline and Telavancin.

TREK
DIAGNOSTIC SYSTEMS
MAGELLAN BIOSCIENCES
www.trekds.com

982 Keynote Circle, Suite 6
 Cleveland, OH 44131

Your **TREK** is Enclosed!
Times

www.trekds.com

Visit TREK at one of our 2010 Trade Shows!

ECCMID	4/10-4/13	Vienna, Austria
ASM	5/24-5/26	San Diego, CA
NACMID	6/14-6/16	Nashua, NH
AACC	7/27-7/29	Anaheim, CA
SWACM	9/1-9/4	San Antonio, TX
SCASM	11/4-11/6	La Jolla, CA
SEACM	11/4-11/6	Greenville, SC

THIS JUST IN:

FDA Clears Three Additional Antimicrobials for Use on Sensititre® IVD MIC Susceptibility Plates:

- **Minocycline** for testing of Enterobacteriaceae, *Acinetobacter* spp. and *Staphylococcus aureus*
- **Telavancin** for testing Gram positive isolates
- **Tigecycline**, now cleared for ***Streptococcus pneumoniae*** testing!